An ageing population and a hip and knee replacement company ought to be a match made in heaven. The shares are down 38 per cent over the past five years and nearly 6 per cent since the beginning of 2024. Seb Jantet, healthcare analyst at Liberum, says the US is still battling with supply issues for hips and knees, but there is potential for upside if the business resolves this. 'Smith & Nephew is reaping the benefits from portfolio shifting toward faster-growth segments and recent R&D efforts, which support higher, sustainable growth,' he says. S&N is far from perfect – but, overlooking the issues, the company is cheap and worth buying for short-term upside.

Source: Daily Mail May 12, 2024 08:46 UTC